CN106362069A - Medicinal composition for treating gastritis, medicated ironing plaster prepared from medicinal composition, and preparation method of medicated ironing plaster - Google Patents
Medicinal composition for treating gastritis, medicated ironing plaster prepared from medicinal composition, and preparation method of medicated ironing plaster Download PDFInfo
- Publication number
- CN106362069A CN106362069A CN201610758528.4A CN201610758528A CN106362069A CN 106362069 A CN106362069 A CN 106362069A CN 201610758528 A CN201610758528 A CN 201610758528A CN 106362069 A CN106362069 A CN 106362069A
- Authority
- CN
- China
- Prior art keywords
- parts
- layer
- phase
- fructus
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000007882 Gastritis Diseases 0.000 title claims abstract description 42
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 239000011505 plaster Substances 0.000 title abstract description 10
- 238000010409 ironing Methods 0.000 title abstract 6
- 238000010438 heat treatment Methods 0.000 claims abstract description 70
- 239000000463 material Substances 0.000 claims abstract description 44
- 230000000694 effects Effects 0.000 claims abstract description 28
- 235000003935 Hippophae Nutrition 0.000 claims abstract description 25
- 241000229143 Hippophae Species 0.000 claims abstract description 25
- 239000002994 raw material Substances 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims description 146
- 239000003795 chemical substances by application Substances 0.000 claims description 54
- 239000000284 extract Substances 0.000 claims description 52
- 239000008194 pharmaceutical composition Substances 0.000 claims description 44
- 239000004745 nonwoven fabric Substances 0.000 claims description 40
- 239000002674 ointment Substances 0.000 claims description 39
- 239000012467 final product Substances 0.000 claims description 31
- 239000000843 powder Substances 0.000 claims description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 29
- 230000007704 transition Effects 0.000 claims description 26
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 25
- 239000004531 microgranule Substances 0.000 claims description 25
- 229940057995 liquid paraffin Drugs 0.000 claims description 21
- 238000002156 mixing Methods 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 16
- 239000000047 product Substances 0.000 claims description 15
- 239000002671 adjuvant Substances 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 13
- 239000011347 resin Substances 0.000 claims description 13
- 229920005989 resin Polymers 0.000 claims description 13
- -1 isopropyl ester Chemical class 0.000 claims description 11
- 230000009466 transformation Effects 0.000 claims description 11
- 239000002131 composite material Substances 0.000 claims description 10
- HVUMOYIDDBPOLL-UHFFFAOYSA-N 2-(3,4-Dihydroxyoxolan-2-yl)-2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)C1OCC(O)C1O HVUMOYIDDBPOLL-UHFFFAOYSA-N 0.000 claims description 9
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 9
- 239000010451 perlite Substances 0.000 claims description 9
- 235000019362 perlite Nutrition 0.000 claims description 9
- 238000003825 pressing Methods 0.000 claims description 9
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 8
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 8
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 8
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 8
- 239000005642 Oleic acid Substances 0.000 claims description 8
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 8
- 238000005520 cutting process Methods 0.000 claims description 8
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 8
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 8
- 239000007800 oxidant agent Substances 0.000 claims description 8
- 230000001590 oxidative effect Effects 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 238000009461 vacuum packaging Methods 0.000 claims description 7
- SIHSSUWJKIEVGQ-UHFFFAOYSA-N 14-methyl-1-(14-methylpentadecoxy)pentadecane Chemical compound CC(C)CCCCCCCCCCCCCOCCCCCCCCCCCCCC(C)C SIHSSUWJKIEVGQ-UHFFFAOYSA-N 0.000 claims description 6
- 239000004166 Lanolin Substances 0.000 claims description 6
- 239000005357 flat glass Substances 0.000 claims description 6
- 229940039717 lanolin Drugs 0.000 claims description 6
- 235000019388 lanolin Nutrition 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 5
- 238000002844 melting Methods 0.000 claims description 5
- 230000008018 melting Effects 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 3
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 3
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims 1
- 238000007711 solidification Methods 0.000 claims 1
- 230000008023 solidification Effects 0.000 claims 1
- 239000004575 stone Substances 0.000 claims 1
- 239000001993 wax Substances 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 abstract description 21
- 239000000126 substance Substances 0.000 abstract description 11
- 238000002560 therapeutic procedure Methods 0.000 abstract description 5
- 241000132012 Atractylodes Species 0.000 abstract description 3
- 230000005284 excitation Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 42
- 239000002585 base Substances 0.000 description 37
- 210000002784 stomach Anatomy 0.000 description 23
- 229940079593 drug Drugs 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 208000002193 Pain Diseases 0.000 description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 201000006549 dyspepsia Diseases 0.000 description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 230000004087 circulation Effects 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 8
- 238000010792 warming Methods 0.000 description 8
- 239000005995 Aluminium silicate Substances 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 206010047700 Vomiting Diseases 0.000 description 7
- 235000012211 aluminium silicate Nutrition 0.000 description 7
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000036528 appetite Effects 0.000 description 6
- 235000019789 appetite Nutrition 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 230000003014 reinforcing effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000008673 vomiting Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010000077 Abdominal mass Diseases 0.000 description 4
- PKPPDYGHKDIKBH-UHFFFAOYSA-N Isopropyl dodecanoic acid Chemical compound CCCCCCCCCC(=O)OC(C)C PKPPDYGHKDIKBH-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000155 melt Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- LNJTUUHDKCPQAA-UHFFFAOYSA-N 1-(4,8-dimethoxyfuro[2,3-b]quinolin-7-yl)oxy-3-methylbut-3-en-2-ol Chemical compound N1=C2C(OC)=C(OCC(O)C(C)=C)C=CC2=C(OC)C2=C1OC=C2 LNJTUUHDKCPQAA-UHFFFAOYSA-N 0.000 description 3
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical compound C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 3
- 206010067171 Regurgitation Diseases 0.000 description 3
- ACVGWSKVRYFWRP-UHFFFAOYSA-N Rutecarpine Chemical compound C1=CC=C2C(=O)N(CCC=3C4=CC=CC=C4NC=33)C3=NC2=C1 ACVGWSKVRYFWRP-UHFFFAOYSA-N 0.000 description 3
- 230000004596 appetite loss Effects 0.000 description 3
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 238000007373 indentation Methods 0.000 description 3
- 150000002596 lactones Chemical class 0.000 description 3
- 208000019017 loss of appetite Diseases 0.000 description 3
- 235000021266 loss of appetite Nutrition 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000001113 umbilicus Anatomy 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 2
- HWFYWIVOYBPLQU-SREVYHEPSA-N Evocarpine Chemical compound C1=CC=C2N(C)C(CCCCCCC\C=C/CCCC)=CC(=O)C2=C1 HWFYWIVOYBPLQU-SREVYHEPSA-N 0.000 description 2
- STRABSCAWZINIF-UHFFFAOYSA-N Juniper camphor Chemical compound C1CCC(C)(O)C2CC(=C(C)C)CCC21C STRABSCAWZINIF-UHFFFAOYSA-N 0.000 description 2
- VHLJDTBGULNCGF-UHFFFAOYSA-N Limonin Natural products CC1(C)OC2CC(=O)OCC23C4CCC5(C)C(CC(=O)C6OC56C4(C)C(=O)CC13)c7cocc7 VHLJDTBGULNCGF-UHFFFAOYSA-N 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- 239000010238 camphora Substances 0.000 description 2
- 229940025250 camphora Drugs 0.000 description 2
- VNWKTOKETHGBQD-AKLPVKDBSA-N carbane Chemical class [15CH4] VNWKTOKETHGBQD-AKLPVKDBSA-N 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000023652 chronic gastritis Diseases 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- SMSBSJNIBCNVES-UHFFFAOYSA-N dihydro-evoxoidine Natural products COc1c2ccoc2nc3c(OC)c(OCC(O)C(C)C)ccc13 SMSBSJNIBCNVES-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- KBDSLGBFQAGHBE-MSGMIQHVSA-N limonin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 KBDSLGBFQAGHBE-MSGMIQHVSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- NDVASEGYNIMXJL-UHFFFAOYSA-N sabinene Chemical compound C=C1CCC2(C(C)C)C1C2 NDVASEGYNIMXJL-UHFFFAOYSA-N 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 230000004206 stomach function Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 2
- NDVASEGYNIMXJL-NXEZZACHSA-N (+)-sabinene Natural products C=C1CC[C@@]2(C(C)C)[C@@H]1C2 NDVASEGYNIMXJL-NXEZZACHSA-N 0.000 description 1
- STRABSCAWZINIF-RBSFLKMASA-N (-)-Eudesm-7(11)-en-4alpha-ol Natural products C1CC[C@@](C)(O)[C@@H]2CC(=C(C)C)CC[C@]21C STRABSCAWZINIF-RBSFLKMASA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- OOCLVMCVOWKECB-UHFFFAOYSA-N 6,6-dimethylbicyclo[3.1.1]heptane-4-carbaldehyde Chemical compound C1C2C(C)(C)C1CCC2C=O OOCLVMCVOWKECB-UHFFFAOYSA-N 0.000 description 1
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 244000141331 Amomum villosum Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 240000008384 Capsicum annuum var. annuum Species 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- QNGQIURXCUHNAT-UHFFFAOYSA-N Eucarvone Chemical compound CC1=CC=CC(C)(C)CC1=O QNGQIURXCUHNAT-UHFFFAOYSA-N 0.000 description 1
- OPQCAZJRIRHZQK-UHFFFAOYSA-N Eucarvone Natural products CC1=CC=CCC(C)(C)C1=O OPQCAZJRIRHZQK-UHFFFAOYSA-N 0.000 description 1
- HWFYWIVOYBPLQU-UHFFFAOYSA-N Evocarpin Natural products C1=CC=C2N(C)C(CCCCCCCC=CCCCC)=CC(=O)C2=C1 HWFYWIVOYBPLQU-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 240000000588 Hericium erinaceus Species 0.000 description 1
- 235000007328 Hericium erinaceus Nutrition 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- RAEOYMOPVHBBKE-UHFFFAOYSA-N Hydroxyevodiamine Natural products CNC1=CC=CC=C1C(=O)N1C(=O)C(NC=2C3=CC=CC=2)=C3CC1 RAEOYMOPVHBBKE-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- MAYJEFRPIKEYBL-OASIGRBWSA-N Obacunone Chemical compound C=1([C@@H]2OC(=O)[C@H]3O[C@@]43[C@]3(C)C(=O)C[C@H]5C(C)(C)OC(=O)C=C[C@]5(C)[C@H]3CC[C@]42C)C=COC=1 MAYJEFRPIKEYBL-OASIGRBWSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 244000292697 Polygonum aviculare Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- BCPAKGGXGLGKIO-UHFFFAOYSA-N Pseudorutaecarpin Natural products C1=CC=C2C(=O)N(CCC3=C4C5=CC=CC=C5N3)C4=NC2=C1 BCPAKGGXGLGKIO-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- YZMKFMIZNSOPSN-XGTMLCIVSA-N Rutaevin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)[C@@H](O)C(=O)[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 YZMKFMIZNSOPSN-XGTMLCIVSA-N 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- MOYAFQVGZZPNRA-UHFFFAOYSA-N Terpinolene Chemical compound CC(C)=C1CCC(C)=CC1 MOYAFQVGZZPNRA-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- KGEKLUUHTZCSIP-HOSYDEDBSA-N [(1s,4s,6r)-1,7,7-trimethyl-6-bicyclo[2.2.1]heptanyl] acetate Chemical compound C1C[C@]2(C)[C@H](OC(=O)C)C[C@H]1C2(C)C KGEKLUUHTZCSIP-HOSYDEDBSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- FAMPSKZZVDUYOS-UHFFFAOYSA-N alpha-Caryophyllene Natural products CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 description 1
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- KQAZVFVOEIRWHN-UHFFFAOYSA-N alpha-thujene Natural products CC1=CCC2(C(C)C)C1C2 KQAZVFVOEIRWHN-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000003457 anti-vomiting effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- TYPSVDGIQAOBAD-UHFFFAOYSA-N atractylone Natural products C1C2(C)CCCC(=C)C2CC2=C1OC=C2C TYPSVDGIQAOBAD-UHFFFAOYSA-N 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 208000020670 canker sore Diseases 0.000 description 1
- 229940117948 caryophyllene Drugs 0.000 description 1
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- XYSMNZWLVJYABK-SFHVURJKSA-N hydroxyevodiamine Chemical compound C1=CC=C2N(C)[C@@H]3C(NC=4C5=CC(O)=CC=4)=C5CCN3C(=O)C2=C1 XYSMNZWLVJYABK-SFHVURJKSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000010271 massa medicata fermentata Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- VSLDMVSILHVDSR-UHFFFAOYSA-N obacunone Natural products CC1(C)OC(=O)C=CC2(C)C1CC(=O)C3(C)C2CCC4(C)C(OC(=O)C5OC345)c6occc6 VSLDMVSILHVDSR-UHFFFAOYSA-N 0.000 description 1
- 150000007823 ocimene derivatives Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012782 phase change material Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- GRWFGVWFFZKLTI-UHFFFAOYSA-N rac-alpha-Pinene Natural products CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- YZMKFMIZNSOPSN-UHFFFAOYSA-N rutaevine Natural products CC1(C)OC2CC(=O)OCC22C1C(=O)C(O)C(C13OC1C(=O)O1)(C)C2CCC3(C)C1C=1C=COC=1 YZMKFMIZNSOPSN-UHFFFAOYSA-N 0.000 description 1
- 229930006696 sabinene Natural products 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- XJPBRODHZKDRCB-UHFFFAOYSA-N trans-alpha-ocimene Natural products CC(=C)CCC=C(C)C=C XJPBRODHZKDRCB-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- YHQGMYUVUMAZJR-UHFFFAOYSA-N α-terpinene Chemical compound CC(C)C1=CC=C(C)CC1 YHQGMYUVUMAZJR-UHFFFAOYSA-N 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N β-pinene Chemical compound C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/02—Compresses or poultices for effecting heating or cooling
- A61F7/03—Compresses or poultices for effecting heating or cooling thermophore, i.e. self-heating, e.g. using a chemical reaction
- A61F7/032—Compresses or poultices for effecting heating or cooling thermophore, i.e. self-heating, e.g. using a chemical reaction using oxygen from the air, e.g. pocket-stoves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H39/00—Devices for locating or stimulating specific reflex points of the body for physical therapy, e.g. acupuncture
- A61H39/06—Devices for heating or cooling such points within cell-life limits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/754—Evodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K5/00—Heat-transfer, heat-exchange or heat-storage materials, e.g. refrigerants; Materials for the production of heat or cold by chemical reactions other than by combustion
- C09K5/02—Materials undergoing a change of physical state when used
- C09K5/06—Materials undergoing a change of physical state when used the change of state being from liquid to solid or vice versa
- C09K5/063—Materials absorbing or liberating heat during crystallisation; Heat storage materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/02—Compresses or poultices for effecting heating or cooling
- A61F2007/0203—Cataplasms, poultices or compresses, characterised by their contents; Bags therefor
- A61F2007/0215—Cataplasms, poultices or compresses, characterised by their contents; Bags therefor containing liquids other than water
- A61F2007/0219—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/02—Compresses or poultices for effecting heating or cooling
- A61F2007/0244—Compresses or poultices for effecting heating or cooling with layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/02—Compresses or poultices for effecting heating or cooling
- A61F2007/0261—Compresses or poultices for effecting heating or cooling medicated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/10—Characteristics of apparatus not provided for in the preceding codes with further special therapeutic means, e.g. electrotherapy, magneto therapy or radiation therapy, chromo therapy, infrared or ultraviolet therapy
- A61H2201/105—Characteristics of apparatus not provided for in the preceding codes with further special therapeutic means, e.g. electrotherapy, magneto therapy or radiation therapy, chromo therapy, infrared or ultraviolet therapy with means for delivering media, e.g. drugs or cosmetics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
- Y02E60/14—Thermal energy storage
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Thermal Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rehabilitation Therapy (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Materials Engineering (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Combustion & Propulsion (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicinal composition for treating gastritis, a medicated ironing plaster prepared from the medicinal composition, and a preparation method of the medicated ironing plaster. The medicinal composition is prepared from the following raw materials in parts by weight: 200-300 parts of white atractylodes rhizome, 150-200 parts of fructus evodiae, 150-200 parts of fructus amomi, 100-150 parts of rhizoma polygoni paleacei, 100-150 parts of fructus amomi rotundus, and 100-150 parts of fructus hippophae. For the traditional Chinese medicinal plaster, the medical instrument is combined for use, the guiding principles of invigorating the spleen, tonifying qi, dispelling cold and the like are adopted, the hot ironing preparation provided by the invention is prepared by virtue of the traditional hot ironing therapy and by utilizing the heating principle of the chemical materials, the synergistic effects of physics and pharmacology are fully exerted, the endogenous excitation effects are enhanced, and the treatment effects aiming at gastritis are remarkable.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, especially relate to a kind of pharmaceutical composition treating gastritis, this medicine group
Medicine that compound is made apts and preparation method thereof.
Background technology
Gastritis is commonly encountered diseases frequently-occurring disease clinically, accounts for starting position in common disease.Gastritis belongs to traditional Chinese medical science gastric abscess model
Farmland, because disease time is longer, how based on weakness of the spleen and stomach, but caused by often seeing the excess pathogen such as qi depression to blood stasis or the wet interior note of water.Slowly
Property superficial gastritiss protracted course of disease, then easily develop into chronic atrophic gastritis, because of the impaired weakness of long-term taste, cause mechanism of qi lose
Adjust, the long blood trouble of disease enters network and becomes the stasis of blood, and blood stasis hinder and form disease in stomach network.Therefore traditional Chinese medical science scholar thinks the treatment Ying Yijian that this is demonstrate,proved
Spleen, QI invigorating, cold expelling etc. are guideline.
The Chinese patent of Application No. 2014101848836, discloses a kind of Chinese medicine treating atrophic gastritis umbilicuss patch and joins
Side and preparation method, described Chinese medicine formula includes Radix Stephaniae Tetrandrae, fragrant lattice skin, the Radix Aucklandiae, Lignum Aquilariae Resinatum, GUIZIHONG, Hericium erinaceus (Bull. Ex Fr.) Pers., Fel Sus domestica, Massa Medicata Fermentata,
Endothelium Corneum Gigeriae Galli (parched), the Radix Linderae, Shi Fupu, Radix Adenophorae (Radix Glehniae), Radix Ophiopogonis.Umbilicuss patch described in this invention provides a kind for the treatment of in addition to endo-medicine
The external treatment mode of chronic atrophic gastritis, has the advantages that convenience, is difficult to recur；The China of Application No. 201110313336x
Patent, discloses a kind of Self-heating traditional Chinese medicine plaster treating chronic gastritiss, this Self-heating traditional Chinese medicine plaster is by hermetic bag and bag
In its interior plaster being bonded together up and down and self-heating bag composition, wherein, described self-heating bag is by venting bags and Bao Qi
Ferrum redox reaction chemical exothermic material composition；Described plaster is made up of backing layer, medicine storing layer and adherent layer, institute
State medicine storing layer to be made up of the effective ingredient of pharmaceutically acceptable substrate and the crude drug being equivalent to matrix weight 40%,
Wherein said effective ingredient is the water extract of the crude drug of following percentage by weight: Pericarpium Citri Reticulatae 10%-30%, flower bud perfume 10%-20%, long-pending
Real 10%-20%, Lay trip 10% one 30%, mountain inspection 20%-40%；It is good that the described Self-heating traditional Chinese medicine plaster of this invention has Transdermal absorption
Advantage with determined curative effect.
But above-mentioned patent there is the problem that
(1) patent one prepares patch after only mixing traditional Chinese medicinal material raw materials, and patch is attached at human body umbilicuss, simple dependence
Human body autologous skin is treated to the Transdermal absorption of medicine, therefore unsatisfactory curative effect；
(2) patent two adds self-heating bag in the Chinese herbs paste of preparation, and patch is attached on human body skin, relies on human body itself skin
Skin generates heat and promotes the absorption to ingredient for the human body to the Transdermal absorption of medicine, self-heating bag, plays the effect for the treatment of gastritis, but patch
After agent is affixed on human body, self-heating bag heating temp under certain environmental conditions due to accumulated temperature effect, temperature can exceed skin tolerance and
To skin damage, there is safety defect.
Content of the invention
In view of this, the purpose of the present invention is for the deficiencies in the prior art, provides a kind of drug regimen treating gastritis
Medicine that thing, this pharmaceutical composition are made apts and preparation method thereof, solves gastritis patch and controls curative effect lifting and safety applications
Problem.
For reaching above-mentioned purpose, the present invention employs the following technical solutions:
A kind of pharmaceutical composition treating gastritis, including the raw material of following weight portion: 200～300 parts of the Rhizoma Atractylodis Macrocephalae, Fructus Evodiae 150～
200 parts, 150～200 parts of Fructus Amomi, 100～150 parts of Rhizoma Polygoni Paleachi, 100～150 parts of Fructus Amomi Rotunduss and 100～150 parts of Fructus Hippophae.
The medicine that a kind of aforementioned pharmaceutical compositions are made apts, and described medicine apts and includes non-woven fabrics, heating sandwich layer (prior art
The chemical heat object of the preparations such as iron powder), phase-change constant-temperature layer, medicament layer and release paper；The ventilative face of heating sandwich layer and painting pressure sensitive adhesive
Non-woven fabrics patch the wing bonding, non-breathable face overlap phase-change constant-temperature layer, on described phase-change constant-temperature layer overlap medicament layer, described medicament layer
Upper covering release paper；
Described heating sandwich layer is chemistry exothermic material of the prior art, and a kind of chemistry exothermic material is by following percentage by weight
Raw material forms: reduced iron powder 40-70%, activated carbon 5-25%, mass concentration are 15% sodium chloride solution 5-25% and Kaolin 5-
30%.
Described phase-change constant-temperature layer includes the raw material of following weight portion: 10～20 parts of oil-base gel, 60～80 parts of phase transition agent and
Microgranule contains 10～20 parts of agent；
Described medicament layer includes ointment, ointment include described treatment gastritis 20～40 parts of the extract extractum of pharmaceutical composition and
60～80 parts of adjuvant.
Preferably, described oil-base gel is heated to the resin melting system of sbs with adding 7～10 parts of liquid paraffin for 1 part by sbs resin
It is obtained.Described liquid paraffin is the liquid paraffin of 200～400 DEG C of fractions；Described phase transition agent is 43～45 DEG C of transformation temperature, average mark
The Polyethylene Glycol of son amount 800～1200；Described microgranule contains the expanded perlite that agent is 50～100 mesh.
Preferably, described accessory package includes 30～65 parts of oil-base gel, 20～40 parts of oiliness solvent, surfactant 5～10
Part and 0.5～1 part of Borneolum Syntheticum.
Preferably, described oiliness solvent is sad isopropyl ester, capric acid isopropyl ester, isopropyl myristate, Palmic acid isopropyl
One of ester and Oleic acid；Described surfactant is in glyceryl monostearate, lanolin isohexadecyl ether and sorbester p18
A kind of.
Preferably, the preparation method of described extract extractum is: weighs the Rhizoma Atractylodis Macrocephalae, Fructus Evodiae, Fructus Amomi, careless blood by formula proportion
Exhaust, Fructus Amomi Rotunduss and Fructus Hippophae, be dried, be crushed to 40～60 mesh, mix to obtain medicinal powder, add total with medicinal powder in medicinal powder
The volume fraction that 20～30 times of quality meter is 70～80% ethanol solution, heating, and twice, united extraction liquid, after merging for reflux, extract,
Extracting solution rotary evaporator be concentrated into solid content be 65～75%, obtain final product extract extractum.
The preparation method that the medicine that a kind of aforementioned pharmaceutical compositions are made apts, comprises the following steps:
(1) pharmacy oxidant layer: the formula proportion according to ointment weighs extract extractum and oil-base gel, oiliness solvent, surface activity
Agent and Borneolum Syntheticum, oil-base gel, oiliness solvent, surfactant and Borneolum Syntheticum mix homogeneously are heated to 60～80 DEG C, when material is complete
Portion's fusing stops heating, is cooled to 50～60 DEG C；It is subsequently adding extract extractum, mixing and stirring obtains ointment, ointment is cold
But coat afterwards on thin non-woven fabrics, obtain final product medicament layer；
(2) phase-change constant-temperature layer processed: mix after 60～80 parts of phase transition agent and microgranule are contained 10～20 parts of heating of agent, melt, gained
In mixture add 10～20 parts fusing oil-base gels stirring mixing, be then cast in plate glass be obtained thickness be 1～
The flexible material of 1.5mm, is superimposed on heat generating core and is obtained final product phase-change constant-temperature layer；
(3) pharmacy is apted: by the ventilative face of heating sandwich layer and the non-woven fabrics bonding scribbling pressure sensitive adhesive, non-breathable face sequentially overlaps phase
Become thermostat layer, medicament layer, then the edge of the nonwoven selvedge of medicament layer and heating sandwich layer is pressed with ultrasonic pressing machine, medicament layer
Upper covering release paper, cross cutting shapes, and vacuum packaging obtains final product product.
The pharmacological action of the present invention is:
The Rhizoma Atractylodis Macrocephalae: the rhizome of the feverfew Rhizoma Atractylodis Macrocephalae, perennial herb, hard with rhizome matter of being used as medicine, it is not easily broken, section is uneven,
Yellow-white is dispersed in light brown, the point-like grease chamber having brown color；Gas delicate fragrance, sweet in the mouth, micro-pungent, the somewhat viscous chewed.Rhizoma Atractylodis Macrocephalae bitter in the mouth,
Sweet, warm in nature, enter spleen, stomach；Have spleen reinforcing, stomach reinforcing, dampness and in, hidroschesis, antiabortive the effect of, for drying damp and strengthening spleen, insufficiency of the spleen food
Few, dyspepsia, chronic diarrhea, edema, hidroschesis, antiabortive.The chemical composition of the Rhizoma Atractylodis Macrocephalae includes: atractylone, atractylol, atractyloxide,
Juniper camphor, atractyloide, hydroxyatractylolide, atractylenolqide, Palmic acid, Fructose, inulin and atractylodes lactone,
And 8- β-ethyoxyl atractylodes lactone, additionally contain vitamin a class material and arginine, proline, Aspartic Acid,
14 kinds of aminoacid such as serine.
Fructus Evodiae: another name Fructus Evodiae, tea are peppery, paint spicy, smelly spicy tree, the pure deep and remote son of left power, rice spicy etc., are rutaceae
The fruit of Fructus Evodiae, Fructus Evodiae and its mutation close to mellow fruit be conventional Chinese medicine.Fructus Evodiae acrid in the mouth, hardship, warm in nature, enter
Liver, stomach, have the effect of warming middle-JIAO, pain relieving, qi-regulating, dampness, radiating pain relieving, stopping nausea and vomiting by lowering the adverse flow of QI, for treating liver stomach deficiency and coldness, the moon of fainting
Headache, the coldness of ZANG-organ is vomited and diarrhoea, abdominal distention, abdominal pain during menstruation, Diarrhoea, vascular hypertension, tinea pedis, hernia, aphthous ulcer, and toothache is wet
Rash, the disease such as impetigo.Fructus Evodiae contains volatile oil, and chemical composition includes evodene, ocimene, obaculactone, Wu Zhu
Cornel lactone alcohol, rutaecarpin, rutaecarpine, wuchuyine, Hydroxyevodiamine, evocarpine, dihydro Fructus Evodiae
Card product alkali, cyclic guanosine monophosphate, also contain limonin, evodine, evodine ethyl ester, obacunone.Also contain flavonoid
As anthocyanin, iso-amylene flavone；Ketone such as evodinone, evogin and steroidal compounds, fatty acid compound.
Fructus Amomi: another name fructus amomi, is mature fruit or the seed of zingiberaceous plant Fructus Amomi or contracting sand, be the traditional Chinese medical science conventional one
Taste aromaticity medicinal material.Fructus Amomi acrid in the mouth, warm in nature, enter spleen, stomach；Have circulation of qi promoting adjust in, stomach function regulating, be amusing, antiabortive the effect of, can be used for
Treatment turbid damp obstructing in middle-JIAO, gastral cavity ruffian is not hungry, Deficiency and coldness of spleen and stomach, vomiting is had loose bowels, pregnancy reactionss, frequent fetal movement.Seeds of Amomum Villosum contains volatile oil
1.7%～3%, chemical composition is mainly d- Camphora, d- Borneolum Syntheticum, borneol acetate, linalool, orange blossom green pepper alcohol and a kind of terpenes.
Rhizoma Polygoni Paleachi: another name: YIKOUXUE, old, old arcus pelvicus of bending over, little public affairs, herb Potentillae cryptotaeniae, hornet, the grass that has been eaten, Polygonaceae Polygonum
Plant red shank knotweed is used as medicine with root stock.Autumn excavates root stock, removes stem and leaf fibrous root, dries.Rhizoma Polygoni Paleachi tepor, toil micro-puckery,
Enter spleen, stomach, kidney three warp, indication: scattered blood hemostasis, therapeutic method to keep the adverse QI flowing downwards pain relieving.Can be used for treatment and control chronic gastritiss, Stomach duodenum is burst
Infectionss, food stagnation, abdominal mass is gathered.
Fructus Amomi Rotunduss: this product is the dry mature fruit of zingiberaceous plant Fructus Amomi Rotunduss.Fructus Amomi Rotunduss acrid in the mouth, warm in nature, enter lung, spleen channel；Have
Removing dampness, circulation of qi promoting, warming middle-JIAO, preventing or arresting vomiting, removing dampness disappear painful abdominal mass, circulation of qi promoting warming middle-JIAO, the effect of appetite-stimulating indigestion-relieving；Can be used for treating the stagnation of QI, dyspepsia, breast
Vexed, abdominal distention, eructation, dysphagic, tell inverse, regurgitation, malaria, turbid damp obstructing in middle-JIAO, anorexia, hygropyrexia is from the beginning of uncomfortable in chest not hungry, cold-damp is vomitted
Inverse, chest and abdomen swelling and pain, the disease such as dyspepsia.Fructus Amomi Rotunduss fruit contain volatile oil, chemical composition include d- Borneolum Syntheticum, d- Camphora, oxalene and
Its epoxide, 1,8- cineole, α-and δ-terpinene, α-and nopinene, caryophyllene, myrcene, myrtanal, Eucarvone,
Terpinene-4-alcohol, sabinene etc..
Fructus Hippophae: another name: vinegar willow；Acid thorn；Dagri cloth, belongs to Elaeangnaceae, Hippophae machaka.Fructus Hippophae feeble QI is fragrant, taste pole
Acid, mild-natured sour in the mouth, can be used for treating gastric duodenal ulcer and dyspepsia etc., to chronic superficial gastritiss, atrophic
The diseases such as gastritis, colitis are evident in efficacy.
The invention has the beneficial effects as follows:
The invention provides the medicine that a kind of pharmaceutical composition treating gastritis, this pharmaceutical composition are made apts and its preparation side
Method, medical instruments are combined, and with spleen invigorating, QI invigorating, cold expelling etc. as guideline, use for reference the chemical material heating of traditional fomentation therapy former
Reason prepares the fomentation agent of the present invention, gives full play to the cooperative effect of physics and pharmacology, enhanced endogenesis priming effect, for stomach
Scorching therapeutic effect is very notable, specifically have following some:
(1) the Six-element Chinese medicine in the pharmaceutical composition of the present invention is with spleen invigorating, QI invigorating, cold expelling etc. as guideline, wherein Rhizoma Atractylodis Macrocephalae taste
Bitter, sweet, warm in nature, there is spleen reinforcing, stomach reinforcing, dampness and middle effect；Fructus Evodiae acrid in the mouth, hardship, warm in nature, there is warming middle-JIAO, pain relieving, qi-regulating,
Dampness, radiating pain relieving, stopping nausea and vomiting by lowering the adverse flow of QI the effect of；Fructus Amomi acrid in the mouth, warm in nature, have circulation of qi promoting adjust in, stomach function regulating, the effect of be amusing；Careless blood
Exhaust tepor, toil micro-puckery, there is the effect of scattered blood hemostasis, therapeutic method to keep the adverse QI flowing downwards pain relieving；Fructus Amomi Rotunduss acrid in the mouth, warm in nature, have removing dampness, circulation of qi promoting, warming middle-JIAO,
Preventing or arresting vomiting, removing dampness disappear painful abdominal mass, circulation of qi promoting warming middle-JIAO, the effect of appetite-stimulating indigestion-relieving；Fructus Hippophae feeble QI is fragrant, taste is extremely sour, mild-natured sour in the mouth, and having treatment can control
Treat the effect of gastric duodenal ulcer and dyspepsia；
Rhizoma Atractylodis Macrocephalae invigorating spleen and reinforcing stomach, drying dampness to eliminate phlegm in Six-element Chinese medicine；Fructus Evodiae and Rhizoma Polygoni Paleachi qi-regulating QI invigorating, eliminating stagnation disappear painful abdominal mass；Fructus Amomi compatibility
Fructus Amomi Rotunduss, Fructus Amomi dampness cold expelling, alleviating distention in middle-JIAO of being amusing, promoting the circulation of QI to relieve pain, Fructus Amomi Rotunduss warming middle-JIAO for eliminating dampness, circulation of qi promoting appetizing, preventing or arresting vomiting pain relieving, the two mutual reinforcement between is
With, removing dampness is amusing, warming spleen and stomach for dispelling cold, promoting the circulation of QI to alleviate the stagnation in middle-JIAO, anti-vomiting；All have the intestines and stomach coordinating effect, share can dispersing the stagnated liver-QI for regulating the stomach, cold expelling stops
Bitterly；The mild-natured sour in the mouth of Fructus Hippophae, invigorating the spleen and replenishing QI, coordinating the actions of various ingredients in a prescription, add adjuvant Borneolum Syntheticum as priming simultaneously, make transdermal administration in ointment
Preparation coordinates the physics transdermal enhancing effect that medicine apts, and accelerates the effect of biophysics such as blood circulation and the sensitive strengthening of meridian point to make
With can be with effectively treatment gastritis.
(2) medicine of the present invention apts, including non-woven fabrics, heating sandwich layer, phase-change constant-temperature layer, medicament layer and release paper；Heating
The ventilative face of sandwich layer and non-woven fabrics bonding, non-breathable face composite phase-change thermostat layer, appendix medicament layer, medicament layer on phase-change constant-temperature layer
Upper covering release paper；Wherein heating layer is chemistry exothermic material of the prior art, and medicament layer includes treating the medicine group of gastritis
The extract extractum of compound and adjuvant；During use, the medicine of the present invention is affixed at human body WEIYU acupoint or ZHONGWAN acupoint, on the one hand
Heating layer plays the effect of fomentation therapy, and medicament layer plays Chinese medicine drug-treating action, the present invention will both organic assembling, heat, medicine
Physics and biochemical factors cooperate, and act synergistically on human meridian point, enhanced endogenesis priming effect, improve human body itself
Immunity, invigorating the spleen and replenishing QI and middle cold expelling, reach the purpose for the treatment of gastritis；On the other hand, the mode of Herbal medicines for external use also reduces length
Phase is taken in high amount of drug and causes toxic and side effects risk.
(3) medicament layer that the medicine of the present invention apts comprises to be passed through by the Rhizoma Atractylodis Macrocephalae, Fructus Evodiae, Fructus Amomi, Rhizoma Polygoni Paleachi, Fructus Amomi Rotunduss and Fructus Hippophae
Alcohol extraction concentrates extract extractum and the adjuvant of gained, and active ingredient wherein in extract extractum has good transdermal administration spy
Property, adjuvant then has the solid-state stability of good dose-storage, and during the calm use of medicine, medicament is in semi liquid state, and medicine is lived
Sexual element greatly improves to the osmotic efficiency of human body, and therefore the therapeutic effect for gastritis is notable.
(4) medicine of the present invention apts and includes one layer of phase-change constant-temperature layer, and described phase-change constant-temperature layer includes oil-base gel, phase transformation
Agent and microgranule contain agent.Phase-change constant-temperature layer can achieve intelligent constant-temperature, and wherein Polyethylene Glycol is a kind of phase-change accumulation energy of function admirable
Material, but turned to liquid using inconvenience by thermal fusible, add expanded perlite and gel therefore in the present invention, precious using expanding
It is continuous phase that Zhu Yan makees adsorbent gel, makes flexible phase-change material, material profile is constant in phase transition process；The medicine of the present invention
Apt in use, the chemical exothermic material in heating layer discharges heat because of air oxidation, and temperature exceedes transformation temperature phase transformation
In thermostat layer, Polyethylene Glycol undergoes phase transition liquefaction absorption heat, prevents the calm temperature of medicine from exceeding setting value and scalds patient skin；With
The prolongation of the calm use time of medicine, in chemical exothermic material, chemical energy reduces, when the calm temperature of medicine begins to decline, composite phase-change
In material, the energy of storage starts to play a role, and the temperature continuing medicine apts maintains between 43～45 DEG C；Therefore, increase phase
After becoming thermostat layer, during the calm whole use of medicine of the one side present invention, its temperature is kept at suitable human drug absorption has
Effect 43～45 DEG C of composition it is ensured that medicine apt will not skin ambustion；On the other hand on the basis of extending the fever time that medicine apts
The treatment time that medicine of the present invention apts significantly extends, therefore excellent to the therapeutic effect of gastritis.
(5) medicine of the present invention apts using herbal composite cheap and easy to get, is made using Modern preparations method, can be dry
Wet defeated resistance, vital energy regualting and blood circulation-promoting, contribute to being mitigated or eliminated the symptoms such as stomachache, distension, inappetence, relatively conventional fomentation is treated
Method long action time, convenience, effectively, are suitable to industrialized production.
Specific embodiment
Embodiment 1
A kind of pharmaceutical composition treating gastritis, including the raw material of following weight portion: 300 parts of the Rhizoma Atractylodis Macrocephalae, Fructus Evodiae 150, Fructus Amomi 200
Part, 100 parts of Rhizoma Polygoni Paleachi, Fructus Amomi Rotunduss 100 and 100 parts of Fructus Hippophae.
Medicine that aforementioned pharmaceutical compositions are made apts, include non-woven fabrics, the sandwich layer that generates heat, phase-change constant-temperature layer, medicament layer and from
Type paper；The ventilative face of heating sandwich layer and non-woven fabrics bonding, non-breathable face composite phase-change thermostat layer, appendix medicament on phase-change constant-temperature layer
Layer, medicament layer covers release paper；
Wherein heating sandwich layer is chemistry exothermic material of the prior art, and a kind of chemistry exothermic material is by following percentage by weight
Raw material forms: reduced iron powder 40%, activated carbon 25%, mass concentration are 15% sodium chloride solution 5% and Kaolin 30%.
Phase-change constant-temperature layer includes 20 parts of oil-base gel by weight, and 70 parts of phase transition agent and microgranule contain 10 parts of agent, oiliness
Gel by 1 part of sbs resin and plus 5～10 parts of liquid paraffin be heated to the resin melting system of sbs and be obtained.Described liquid paraffin is 200
The liquid paraffin of～400 DEG C of fractions；Described phase transition agent is 43～45 DEG C of transformation temperature, the poly- second two of mean molecule quantity 800～1200
Alcohol；Described microgranule contains the expanded perlite that agent is 50～100 mesh；
Medicament layer includes ointment, and ointment includes 30 parts of the extract extractum of pharmaceutical composition and the adjuvant 70 of described treatment gastritis
Part；The preparation method of extract extractum is: weighs the Rhizoma Atractylodis Macrocephalae, Fructus Evodiae, Fructus Amomi, Rhizoma Polygoni Paleachi, Fructus Amomi Rotunduss and Fructus Hippophae by formula proportion, does
Dry, be crushed to 40～60 mesh, mix to obtain medicinal powder, add 20 times in terms of medicinal powder gross mass of volume in medicinal powder
Fraction be 70% ethanol solution, heating, reflux, extract, twice, united extraction liquid, the extracting solution rotary evaporator after merging concentrates
It is 65% to solid content, obtain final product extract extractum；Accessory package includes 30 parts of oil-base gel, sad 40 parts of isopropyl ester, glycerol monostearate
5 parts of ester and 1 part of Borneolum Syntheticum.
The preparation method that the medicine that aforementioned pharmaceutical compositions are made apts, comprises the following steps:
(1) pharmacy oxidant layer: the formula proportion according to ointment weighs extract extractum and oil-base gel, sad isopropyl ester, single Hard Fat
Acid glyceride and Borneolum Syntheticum, oil-base gel, sad isopropyl ester, glyceryl monostearate and Borneolum Syntheticum mix homogeneously are heated to 60 DEG C,
When material all melts stopping heating, it is cooled to 50 DEG C；It is subsequently adding extract extractum, mixing and stirring obtains ointment, medicine
Coat on thin non-woven fabrics after cream cooling, obtain final product medicament layer；
(2) phase-change constant-temperature layer processed: mix after 70 parts of phase transition agent and microgranule are contained 10 parts of heating of agent, melt, in gained mixture
Add the oil-base gel stirring mixing of 20 parts of fusings, be then cast and be obtained, in plate glass, the flexible material that thickness is 1.5mm, will
It is superimposed on heat generating core and obtains final product phase-change constant-temperature layer；
(3) pharmacy is apted: by the ventilative face of heating sandwich layer and the non-woven fabrics bonding scribbling pressure sensitive adhesive, non-breathable face sequentially overlaps phase
Become thermostat layer, medicament layer, then the edge of the thin non-woven fabrics of medicament layer and heating sandwich layer is pressed with ultrasonic pressing machine, medicament layer
Upper covering release paper, cross cutting shapes, and packs and obtains final product product.
Embodiment 2
A kind of pharmaceutical composition treating gastritis, including the raw material of following weight portion: 250 parts of the Rhizoma Atractylodis Macrocephalae, Fructus Evodiae 150, Fructus Amomi 150
Part, 150 parts of Rhizoma Polygoni Paleachi, Fructus Amomi Rotunduss 150 and 100 parts of Fructus Hippophae.
Medicine that aforementioned pharmaceutical compositions are made apts, include non-woven fabrics, the sandwich layer that generates heat, phase-change constant-temperature layer, medicament layer and from
Type paper；The ventilative face of heating sandwich layer and non-woven fabrics bonding, non-breathable face composite phase-change thermostat layer, appendix medicament on phase-change constant-temperature layer
Layer, medicament layer covers release paper；
Wherein heating sandwich layer is chemistry exothermic material of the prior art, and a kind of chemistry exothermic material is by following percentage by weight
Raw material forms: reduced iron powder 60%, activated carbon 5%, mass concentration are 15% sodium chloride solution 25% and Kaolin 10%.
Phase-change constant-temperature layer includes 20 parts of oil-base gel by weight, and 70 parts of phase transition agent and microgranule contain 10 parts of agent, oiliness
Gel by 1 part of sbs resin and plus 5～10 parts of liquid paraffin be heated to the resin melting system of sbs and be obtained.Described liquid paraffin is 200
The liquid paraffin of～400 DEG C of fractions；Described phase transition agent is 43～45 DEG C of transformation temperature, the poly- second two of mean molecule quantity 800～1200
Alcohol；Described microgranule contains the expanded perlite that agent is 50～100 mesh；
Medicament layer includes ointment, and ointment includes 30 parts of the extract extractum of pharmaceutical composition and the adjuvant 70 of described treatment gastritis
Part；The preparation method of extract extractum is: weighs the Rhizoma Atractylodis Macrocephalae, Fructus Evodiae, Fructus Amomi, Rhizoma Polygoni Paleachi, Fructus Amomi Rotunduss and Fructus Hippophae by formula proportion, does
Dry, be crushed to 60 mesh, mix to obtain medicinal powder, add 20 times in terms of medicinal powder gross mass of volume fraction in medicinal powder
For 80% ethanol solution, heat, reflux, extract, twice, united extraction liquid, the extracting solution rotary evaporator after merging is concentrated into solid
Content is 75%, obtains final product extract extractum；Accessory package includes 65 parts of oil-base gel, 20 parts of capric acid isopropyl ester, lanolin isohexadecyl ether
10 parts and 0.5 part of Borneolum Syntheticum.
The preparation method that the medicine that aforementioned pharmaceutical compositions are made apts, comprises the following steps:
(1) pharmacy oxidant layer: the formula proportion according to ointment weighs extract extractum and oil-base gel, capric acid isopropyl ester, lanoline
Polyoxyethylene ether and Borneolum Syntheticum, oil-base gel, capric acid isopropyl ester, lanolin isohexadecyl ether and Borneolum Syntheticum mix homogeneously are heated to
80 DEG C, when material all melts stopping heating, it is cooled to 60 DEG C；It is subsequently adding extract extractum, mixing and stirring obtains medicine
Cream, coats on thin non-woven fabrics after ointment cooling, obtains final product medicament layer；
(2) phase-change constant-temperature layer processed: mix after 70 parts of phase transition agent and microgranule are contained 10 parts of heating of agent, melt, in gained mixture
Add the oil-base gel stirring mixing of 20 parts of fusings, be then cast and be obtained, in plate glass, the flexible material that thickness is 1.5mm, will
It is superimposed on heat generating core and obtains final product phase-change constant-temperature layer；
(3) pharmacy is apted: by the ventilative face of heating sandwich layer and the non-woven fabrics bonding scribbling pressure sensitive adhesive, non-breathable face sequentially overlaps phase
Become thermostat layer, medicament layer, then the edge of the thin non-woven fabrics of medicament layer and heating sandwich layer is pressed with ultrasonic pressing machine, medicament layer
Upper covering release paper, cross cutting shapes, and vacuum packaging obtains final product product.
Embodiment 3
A kind of pharmaceutical composition treating gastritis, including the raw material of following weight portion: 200 parts of the Rhizoma Atractylodis Macrocephalae, Fructus Evodiae 150, Fructus Amomi 100
Part, 200 parts of Rhizoma Polygoni Paleachi, Fructus Amomi Rotunduss 200 and 100 parts of Fructus Hippophae.
Medicine that aforementioned pharmaceutical compositions are made apts, include non-woven fabrics, the sandwich layer that generates heat, phase-change constant-temperature layer, medicament layer and from
Type paper；The ventilative face of heating sandwich layer and non-woven fabrics bonding, non-breathable face composite phase-change thermostat layer, appendix medicament on phase-change constant-temperature layer
Layer, medicament layer covers release paper；
Wherein heating sandwich layer is chemistry exothermic material of the prior art, and a kind of chemistry exothermic material is by following percentage by weight
Raw material forms: reduced iron powder 50%, activated carbon 15%, mass concentration are 15% sodium chloride solution 20% and Kaolin 15%.
Phase-change constant-temperature layer includes 20 parts of oil-base gel by weight, and 70 parts of phase transition agent and microgranule contain 10 parts of agent, oiliness
Gel by 1 part of sbs resin and plus 5～10 parts of liquid paraffin be heated to the resin melting system of sbs and be obtained.Described liquid paraffin is 200
The liquid paraffin of～400 DEG C of fractions；Described phase transition agent is 43～45 DEG C of transformation temperature, the poly- second two of mean molecule quantity 800～1200
Alcohol；Described microgranule contains the expanded perlite that agent is 50～100 mesh；
Medicament layer includes ointment, and ointment includes 20 parts of the extract extractum of pharmaceutical composition and the adjuvant 80 of described treatment gastritis
Part；The preparation method of extract extractum is: weighs the Rhizoma Atractylodis Macrocephalae, Fructus Evodiae, Fructus Amomi, Rhizoma Polygoni Paleachi, Fructus Amomi Rotunduss and Fructus Hippophae by formula proportion, does
Dry, be crushed to 50 mesh, mix to obtain medicinal powder, add 25 times in terms of medicinal powder gross mass of volume fraction in medicinal powder
For 70% ethanol solution, heat, reflux, extract, twice, united extraction liquid, the extracting solution rotary evaporator after merging is concentrated into solid
Content is 70%, obtains final product extract extractum；Accessory package include 48 parts of oil-base gel, 30 parts of isopropyl myristate, 7 parts of sorbester p18 and
1 part of Borneolum Syntheticum.
The preparation method that the medicine that aforementioned pharmaceutical compositions are made apts, comprises the following steps:
(1) pharmacy oxidant layer: the formula proportion according to ointment weighs extract extractum and oil-base gel, isopropyl myristate, department
Disk 60 and Borneolum Syntheticum, oil-base gel, isopropyl myristate, sorbester p18 and Borneolum Syntheticum mix homogeneously are heated to 70 DEG C, when material is complete
Portion's fusing stops heating, is cooled to 55 DEG C；It is subsequently adding extract extractum, mixing and stirring obtains ointment, after ointment cooling
Coat on thin non-woven fabrics, obtain final product medicament layer；
(2) phase-change constant-temperature layer processed: mix after 70 parts of phase transition agent and microgranule are contained 10 parts of heating of agent, melt, in gained mixture
Add the oil-base gel stirring mixing of 20 parts of fusings, be then cast and be obtained, in plate glass, the flexible material that thickness is 1.2mm, will
It is superimposed on heat generating core and obtains final product phase-change constant-temperature layer；
(3) pharmacy is apted: by the ventilative face of heating sandwich layer and the non-woven fabrics bonding scribbling pressure sensitive adhesive, non-breathable face sequentially overlaps phase
Become thermostat layer, medicament layer, then the edge of the thin non-woven fabrics of medicament layer and heating sandwich layer is pressed with ultrasonic pressing machine, medicament layer
Upper covering release paper, cross cutting shapes, and vacuum packaging obtains final product product.
Embodiment 4
A kind of pharmaceutical composition treating gastritis, including the raw material of following weight portion: 200 parts of the Rhizoma Atractylodis Macrocephalae, 200 parts of Fructus Evodiae, Fructus Amomi
150 parts, 150 parts of Rhizoma Polygoni Paleachi, Fructus Amomi Rotunduss 100 and 150 parts of Fructus Hippophae.
Medicine that aforementioned pharmaceutical compositions are made apts, include non-woven fabrics, the sandwich layer that generates heat, phase-change constant-temperature layer, medicament layer and from
Type paper；The ventilative face of heating sandwich layer and non-woven fabrics bonding, non-breathable face composite phase-change thermostat layer, appendix medicament on phase-change constant-temperature layer
Layer, medicament layer covers release paper；
Wherein heating sandwich layer is chemistry exothermic material of the prior art, and a kind of chemistry exothermic material is by following percentage by weight
Raw material forms: reduced iron powder 50%, activated carbon 15%, mass concentration are 15% sodium chloride solution 20% and Kaolin 15%.
Phase-change constant-temperature layer includes 8 parts of oil-base gel by weight, and 90 parts of phase transition agent and microgranule contain 4 parts of agent, and oiliness is coagulated
Glue proportions with mass ratio as 1:8 by sbs resin and liquid paraffin, described liquid paraffin is the liquid of 200～400 DEG C of fractions
Body paraffin；Described phase transition agent is 43～45 DEG C of transformation temperature, the Polyethylene Glycol of mean molecule quantity 800～1200；Described microgranule contains
Agent is the expanded perlite of 40 mesh.
Medicament layer includes ointment, and ointment includes 40 parts of the extract extractum of pharmaceutical composition and the adjuvant of described treatment gastritis
60 parts；The preparation method of extract extractum is: weigh the Rhizoma Atractylodis Macrocephalae, Fructus Evodiae, Fructus Amomi, Rhizoma Polygoni Paleachi, Fructus Amomi Rotunduss and Fructus Hippophae by formula proportion,
It is dried, is crushed to 40 mesh, mixes to obtain medicinal powder, add 20 times in terms of medicinal powder gross mass of volume integral in medicinal powder
Number be 70% ethanol solution, heating, reflux, extract, twice, united extraction liquid, the extracting solution rotary evaporator after merging is concentrated into
Solid content is 75%, obtains final product extract extractum；Accessory package include 35 parts of oil-base gel, 40 parts of isopropyl palmitate, 5 parts of sorbester p18 and
1 part of Borneolum Syntheticum.
The preparation method that the medicine that aforementioned pharmaceutical compositions are made apts, comprises the following steps:
(1) pharmacy oxidant layer: the formula proportion according to ointment weighs extract extractum and oil-base gel, isopropyl palmitate, span
60 and Borneolum Syntheticum, oil-base gel, isopropyl palmitate, sorbester p18 and Borneolum Syntheticum mix homogeneously are heated to 80 DEG C, when material all melts
Change and stop heating, be cooled to 60 DEG C；It is subsequently adding extract extractum, mixing and stirring obtains ointment, is coated with after ointment cooling
On thin non-woven fabrics, obtain final product medicament layer；
(2) phase-change constant-temperature layer processed: mix after 70 parts of phase transition agent and microgranule are contained 10 parts of heating of agent, melt, in gained mixture
Add the oil-base gel stirring mixing of 20 parts of fusings, be then cast and be obtained, in plate glass, the flexible material that thickness is 1.4mm, will
It is superimposed on heat generating core and obtains final product phase-change constant-temperature layer；
(3) pharmacy is apted: by the ventilative face of heating sandwich layer and the non-woven fabrics bonding scribbling pressure sensitive adhesive, non-breathable face sequentially overlaps phase
Become thermostat layer, medicament layer, then the edge of the thin non-woven fabrics of medicament layer and heating sandwich layer is pressed with ultrasonic pressing machine, medicament layer
Upper covering release paper, cross cutting shapes, and vacuum packaging obtains final product product.
Embodiment 5
A kind of pharmaceutical composition treating gastritis, including the raw material of following weight portion: 300 parts of the Rhizoma Atractylodis Macrocephalae, 150 parts of Fructus Evodiae, Fructus Amomi
200 parts, 100 parts of Rhizoma Polygoni Paleachi, Fructus Amomi Rotunduss 150 and 100 parts of Fructus Hippophae.
Medicine that aforementioned pharmaceutical compositions are made apts, include non-woven fabrics, the sandwich layer that generates heat, phase-change constant-temperature layer, medicament layer and from
Type paper；The ventilative face of heating sandwich layer and non-woven fabrics bonding, non-breathable face composite phase-change thermostat layer, appendix medicament on phase-change constant-temperature layer
Layer, medicament layer covers release paper；
Wherein heating sandwich layer is chemistry exothermic material of the prior art, and a kind of chemistry exothermic material is by following percentage by weight
Raw material forms: reduced iron powder 60%, activated carbon 5%, mass concentration are 15% sodium chloride solution 25% and Kaolin 10%.
Phase-change constant-temperature layer includes 9 parts of oil-base gel by weight, and 89 parts of phase transition agent and microgranule contain 5 parts of agent, and oiliness is coagulated
Glue proportions with mass ratio as 1:9 by sbs resin and liquid paraffin, described liquid paraffin is the liquid of 200～400 DEG C of fractions
Body paraffin；Described phase transition agent is 43～45 DEG C of transformation temperature, the Polyethylene Glycol of mean molecule quantity 800～1200；Described microgranule contains
Agent is the expanded perlite of 45 mesh.
Medicament layer includes ointment, and ointment includes 25 parts of the extract extractum of pharmaceutical composition and the adjuvant of described treatment gastritis
75 parts；The preparation method of extract extractum is: weigh the Rhizoma Atractylodis Macrocephalae, Fructus Evodiae, Fructus Amomi, Rhizoma Polygoni Paleachi, Fructus Amomi Rotunduss and Fructus Hippophae by formula proportion,
It is dried, is crushed to 50 mesh, mixes to obtain medicinal powder, add 25 times in terms of medicinal powder gross mass of volume integral in medicinal powder
Number be 80% ethanol solution, heating, reflux, extract, twice, united extraction liquid, the extracting solution rotary evaporator after merging is concentrated into
Solid content is 65%, obtains final product extract extractum；Accessory package includes 40 parts of oil-base gel, 35 parts of Oleic acid, 6 parts of lanolin isohexadecyl ether
With 0.7 part of Borneolum Syntheticum.
The preparation method that the medicine that aforementioned pharmaceutical compositions are made apts, comprises the following steps:
(1) pharmacy oxidant layer: the formula proportion according to ointment weighs extract extractum and oil-base gel, Oleic acid, lanoline polyoxy second
Alkene ether and Borneolum Syntheticum, oil-base gel, Oleic acid, lanolin isohexadecyl ether and Borneolum Syntheticum mix homogeneously are heated to 80 DEG C, when material is complete
Portion's fusing stops heating, is cooled to 50 DEG C；It is subsequently adding extract extractum, mixing and stirring obtains ointment, after ointment cooling
Coat on thin non-woven fabrics, obtain final product medicament layer；
(2) phase-change constant-temperature layer processed: phase transition agent and microgranule are contained agent and mixes for after 1:4 heating, fusing in mass ratio, gained mixes
The oil-base gel adding 1/3 mixture gross mass in thing stirs mixing, is then cast and is obtained, in flat board, the flexibility that thickness is 1.5mm
Material layer obtains final product phase-change constant-temperature layer；
(3) pharmacy is apted: by the ventilative face of heating sandwich layer and the non-woven fabrics bonding scribbling pressure sensitive adhesive, non-breathable face sequentially overlaps phase
Become thermostat layer, medicament layer, then the edge of the thin non-woven fabrics of medicament layer and heating sandwich layer is pressed with ultrasonic pressing machine, medicament layer
Upper covering release paper, cross cutting shapes, and vacuum packaging obtains final product product.
Embodiment 6
A kind of pharmaceutical composition treating gastritis, including the raw material of following weight portion: 250 parts of the Rhizoma Atractylodis Macrocephalae, 175 parts of Fructus Evodiae, Fructus Amomi
175 parts, 125 parts of Rhizoma Polygoni Paleachi, Fructus Amomi Rotunduss 125 and 125 parts of Fructus Hippophae.
Medicine that aforementioned pharmaceutical compositions are made apts, include non-woven fabrics, the sandwich layer that generates heat, phase-change constant-temperature layer, medicament layer and from
Type paper；The ventilative face of heating sandwich layer and non-woven fabrics bonding, non-breathable face composite phase-change thermostat layer, appendix medicament on phase-change constant-temperature layer
Layer, medicament layer covers release paper；
Wherein heating sandwich layer is chemistry exothermic material of the prior art, and a kind of chemistry exothermic material is by following percentage by weight
Raw material forms: reduced iron powder 40%, activated carbon 25%, mass concentration are 15% sodium chloride solution 5% and Kaolin 30%.
Phase-change constant-temperature layer includes 12 parts of oil-base gel by weight, and 88 parts of phase transition agent and microgranule contain 6 parts of agent, and oiliness is coagulated
Glue proportions with mass ratio as 1:10 by sbs resin and liquid paraffin, described liquid paraffin is 200～400 DEG C of fractions
Liquid paraffin；Described phase transition agent is 43～45 DEG C of transformation temperature, the Polyethylene Glycol of mean molecule quantity 800～1200；Described microgranule bag
Supporting agent is the expanded perlite of 50 mesh.
Medicament layer includes ointment, and ointment includes 35 parts of the extract extractum of pharmaceutical composition and the adjuvant of described treatment gastritis
65 parts；The preparation method of extract extractum is: weigh the Rhizoma Atractylodis Macrocephalae, Fructus Evodiae, Fructus Amomi, Rhizoma Polygoni Paleachi, Fructus Amomi Rotunduss and Fructus Hippophae by formula proportion,
It is dried, is crushed to 40 mesh, mixes to obtain medicinal powder, add 20 times in terms of medicinal powder gross mass of volume integral in medicinal powder
Number be 70% ethanol solution, heating, reflux, extract, twice, united extraction liquid, the extracting solution rotary evaporator after merging is concentrated into
Solid content is 70%, obtains final product extract extractum；Accessory package includes 45 parts of oil-base gel, 30 parts of Oleic acid, 7 parts of sorbester p18 and Borneolum Syntheticum 0.6
Part.
The preparation method that the medicine that aforementioned pharmaceutical compositions are made apts, comprises the following steps:
(1) pharmacy oxidant layer: the formula proportion according to ointment weighs extract extractum and oil-base gel, Oleic acid, sorbester p18 and Borneolum Syntheticum,
By oil-base gel, Oleic acid, sorbester p18 and Borneolum Syntheticum mix homogeneously, it is heated to 80 DEG C, when material all melts stopping heating, be cooled to
60℃；It is subsequently adding extract extractum, mixing and stirring obtains ointment, coats on thin non-woven fabrics, obtain final product after ointment cooling
Medicament layer；
(2) phase-change constant-temperature layer processed: phase transition agent and microgranule are contained agent and mixes for after 1:3 heating, fusing in mass ratio, gained mixes
The oil-base gel adding 1/3 mixture gross mass in thing stirs mixing, is then cast and is obtained, in flat board, the flexible material that thickness is 1mm
The bed of material obtains final product phase-change constant-temperature layer；
(3) pharmacy is apted: by the ventilative face of heating sandwich layer and the non-woven fabrics bonding scribbling pressure sensitive adhesive, non-breathable face sequentially overlaps phase
Become thermostat layer, medicament layer, then the edge of the thin non-woven fabrics of medicament layer and heating sandwich layer is pressed with ultrasonic pressing machine, medicament layer
Upper covering release paper, cross cutting shapes, and vacuum packaging obtains final product product.
Embodiment 7
A kind of pharmaceutical composition treating gastritis, including the raw material of following weight portion: 240 parts of the Rhizoma Atractylodis Macrocephalae, 180 parts of Fructus Evodiae, Fructus Amomi
170 parts, 130 parts of Rhizoma Polygoni Paleachi, Fructus Amomi Rotunduss 110 and 140 parts of Fructus Hippophae.
Medicine that aforementioned pharmaceutical compositions are made apts and preparation method thereof all same as Example 3.
Embodiment 8
A kind of pharmaceutical composition treating gastritis, including the raw material of following weight portion: 220 parts of the Rhizoma Atractylodis Macrocephalae, 160 parts of Fructus Evodiae, Fructus Amomi
190 parts, 110 parts of Rhizoma Polygoni Paleachi, Fructus Amomi Rotunduss 140 and 130 parts of Fructus Hippophae.
Medicine that aforementioned pharmaceutical compositions are made apts and preparation method thereof all same as Example 5.
Clinical trial
First, physical data
From in January, 2015 in January, 2016, observe the gastritis sufferer 36 of syndrome of deficient cold of spleen and stomach, wherein man 21, female 15, year
31 to 68 years old ages.
2nd, diagnostic criteria
By tcm diagnosis standard with reference to the CM syndrome differentiation criterion with regard to syndrome of deficient cold of spleen and stomach gastritis in " Chinese Internal Medicine ", symptoms include: stomach is hidden
Pain or gastral cavilty distension, pain relieved by pressing happiness is warm, and clear water is vomitted in indigestion and loss of appetite loose stool, the lazy speech of shortness of breath, and limb is soft weak, thready and weak pulse, pale tongue, Bian You
Indentation.
3rd, efficacy assessment standard
Effective: clinical symptoms and sign disappear substantially, appetite is normal, and mild disturbance disappears；
Effective: clinical symptoms and sign substantially mitigate, appetite increases, and spirit takes a turn for the better；
Invalid: clinical symptoms and sign no improve criterion of therapeutical effect.
4th, therapeutic scheme
The calm external application of medicine made using the pharmaceutical composition that product of the present invention treats gastritis, is affixed on WEIYU acupoint or ZHONGWAN acupoint.Often
Day one pastes, and continuous using 6 days is a course for the treatment of.
5th, statistical result
Totally 36, effective 21, effective 13, invalid 2, total effective rate 94.4%.
Model case
Case 1: week certain, female, 36 years old, teacher, Henan Xixia Mine people.Patient's readme chronic dietary is irregular, often feels in recent years
Stomach dull pain, indigestion and loss of appetite loose stool, eat acid regurgitation after meal, in March, 2015, and started to stick product of the present invention, stick medicine 1 of the present invention
After the individual course for the treatment of, clinical symptoms and sign disappear substantially, and appetite recovers normal, and mild disturbance disappears.After half a year, Effect of follow-up visit by telephone be not
Recurrence.
Case 2: gold certain, man, 49 years old, workman, Zhengzhou, henan people.Patient's readme for many years indigestion and loss of appetite loose stool, vomits clear water,
The lazy speech of shortness of breath, lean body mass, in June, 2015, start to stick product of the present invention, after sticking 2 courses for the treatment of of medicine of the present invention, clinical condition
Shape and sign substantially mitigate, and appetite increases, and spirit takes a turn for the better.After half a year, Effect of follow-up visit by telephone does not recur.
Case 3: Wang, man, 53 years old, civil servant, Henan people from Xuchang.Patient's readme is because of appetite always after one time wind and cold is caught a cold
Depressed, epigastric distending pain, limb is soft weak, tcm diagnosis thready and weak pulse, pale tongue, while there being indentation, in January, 2016 starts to stick the present invention
After 1.5 courses for the treatment of of product, clinical symptoms and sign disappear substantially, and appetite recovers normal, and mild disturbance disappears.After half a year phone with
Visit and do not recurred.
Case 4: slowly certain, female, 60 years old, peasant.Patient's readme is dried after once eating out and is caught a cold, after always stomach twist
Bitterly, acid regurgitation water after meal, body is gradually become thin, and limb is soft weak, and tcm diagnosis find thready and weak pulse, pale tongue, while there being indentation, are diagnosed as
The gastritis causing because of syndrome of deficient cold of spleen and stomach.In October, 2015, after starting to stick 2 courses for the treatment of of product of the present invention, the clinic such as stomach angor
Symptom disappears substantially, and weight recovery is normal.After half a year, Effect of follow-up visit by telephone does not recur.
Finally illustrate, only in order to technical scheme to be described and unrestricted, this area is common for above example
Other modifications or equivalent that technical staff is made to technical scheme, without departing from technical solution of the present invention
Spirit and scope, all should cover in the middle of scope of the presently claimed invention.
Claims (7)
1. a kind of pharmaceutical composition treating gastritis is it is characterised in that include the raw material of following weight portion: the Rhizoma Atractylodis Macrocephalae 200～300
Part, 150～200 parts of Fructus Evodiae, 150～200 parts of Fructus Amomi, 100～150 parts of Rhizoma Polygoni Paleachi, 100～150 parts of Fructus Amomi Rotunduss and Fructus Hippophae 100～
150 parts.
2. a kind of inclusion it is characterised in that described medicine apts of being apted using the medicine that the pharmaceutical composition described in claim 1 is made
Non-woven fabrics, heating sandwich layer, phase-change constant-temperature layer, medicament layer and release paper；The ventilative face of heating sandwich layer and non-woven fabrics bonding, non-breathable
Face composite phase-change thermostat layer, appendix medicament layer on described phase-change constant-temperature layer, described medicament layer covers release paper；
Described phase-change constant-temperature layer includes the raw material of following weight portion: 10～20 parts of oil-base gel, 60～80 parts of phase transition agent and microgranule
Contain 10～20 parts of agent；
Described medicament layer includes ointment, and ointment includes 20～40 parts of extract extractum and the adjuvant 60～80 of described pharmaceutical composition
Part.
3. medicine according to claim 2 apts it is characterised in that described oil-base gel is by 1 part of sbs resin and liquid feeding body stone
5～10 parts of wax is heated to the resin melting system of sbs and is obtained；Described liquid paraffin is the liquid paraffin of 200～400 DEG C of fractions；Described
Phase transition agent is 43～45 DEG C of transformation temperature, the Polyethylene Glycol of mean molecule quantity 800～1200；It is 50～100 that described microgranule contains agent
Purpose expanded perlite.
4. medicine according to claim 2 apt it is characterised in that described adjuvant include in parts by weight oil-base gel 30～
65 parts, 20～40 parts of oiliness solvent, 5～10 parts of surfactant and 0.5～1 part of Borneolum Syntheticum.
5. medicine according to claim 4 apts it is characterised in that described oiliness solvent is sad isopropyl ester, capric acid isopropyl
One of ester, isopropyl myristate, isopropyl palmitate and Oleic acid；Described surfactant be glyceryl monostearate,
One of lanolin isohexadecyl ether and sorbester p18.
6. medicine according to claim 2 apts it is characterised in that the preparation method of described extract extractum is: by formula
Ratio weighs the Rhizoma Atractylodis Macrocephalae, Fructus Evodiae, Fructus Amomi, Rhizoma Polygoni Paleachi, Fructus Amomi Rotunduss and Fructus Hippophae, is dried, is crushed to 40～60 mesh, mixes to obtain medicinal material powder
End, adds the volume fraction counting 20～30 times with medicinal powder gross mass for 70～80% ethanol solution in medicinal powder, plus
Heat, reflux, extract, twice, united extraction liquid, the extracting solution rotary evaporator after merging be concentrated into solid content be 65～75%, that is,
Obtain extract extractum.
7. the preparation method that the medicine as described in a kind of any one as claim 2～6 apts is it is characterised in that comprise the following steps:
(1) pharmacy oxidant layer: the formula proportion according to ointment weighs extract extractum and oil-base gel, oiliness solvent, surface activity
Agent and Borneolum Syntheticum, oil-base gel, oiliness solvent, surfactant and Borneolum Syntheticum mix homogeneously are heated to 60～80 DEG C, when material is complete
Portion's fusing stops heating, is cooled to 50～60 DEG C；It is subsequently adding extract extractum, mixing and stirring obtains ointment, ointment is cold
But coat solidification on thin non-woven fabrics afterwards, obtain final product medicament layer；
(2) phase-change constant-temperature layer processed: contain 10～20 parts of mixing of agent by adding microgranule after 60～80 parts of heating fusings of phase transition agent, gained mixes
The oil-base gel stirring mixing of 10～20 parts of fusings is added, being then cast and thickness being obtained in plate glass is 1～1.5mm in compound
Flexible material, be superimposed on heat generating core and obtained final product phase-change constant-temperature layer；
(3) pharmacy is apted: by the ventilative face of heating sandwich layer and the non-woven fabrics bonding scribbling pressure sensitive adhesive, non-breathable face sequentially overlaps phase
Become thermostat layer, medicament layer, then pressed with ultrasonic pressing machine by the nonwoven selvedge of medicament layer with the edge of heating sandwich layer, medicament
Release paper is covered on layer, cross cutting shapes, and vacuum packaging obtains final product product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610758528.4A CN106362069A (en) | 2016-08-30 | 2016-08-30 | Medicinal composition for treating gastritis, medicated ironing plaster prepared from medicinal composition, and preparation method of medicated ironing plaster |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610758528.4A CN106362069A (en) | 2016-08-30 | 2016-08-30 | Medicinal composition for treating gastritis, medicated ironing plaster prepared from medicinal composition, and preparation method of medicated ironing plaster |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106362069A true CN106362069A (en) | 2017-02-01 |
Family
ID=57900817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610758528.4A Pending CN106362069A (en) | 2016-08-30 | 2016-08-30 | Medicinal composition for treating gastritis, medicated ironing plaster prepared from medicinal composition, and preparation method of medicated ironing plaster |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106362069A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109589203A (en) * | 2018-10-22 | 2019-04-09 | 清华大学 | The heating paste of temperature control film and the spontaneous hotting mask of constant temperature based on organic phase-change |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102940835A (en) * | 2012-11-08 | 2013-02-27 | 西安福安创意咨询有限责任公司 | Traditional Chinese medicine for treating peptic ulcer |
| CN105125674A (en) * | 2015-09-15 | 2015-12-09 | 河南省超亚医药器械有限公司 | Medicament for treating hyperostosis and medicament-separated moxibustion of medicament |
| CN105147446A (en) * | 2015-09-30 | 2015-12-16 | 河南省超亚医药器械有限公司 | Intelligent constant-temperature hot-compressing medicine patch |
-
2016
- 2016-08-30 CN CN201610758528.4A patent/CN106362069A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102940835A (en) * | 2012-11-08 | 2013-02-27 | 西安福安创意咨询有限责任公司 | Traditional Chinese medicine for treating peptic ulcer |
| CN105125674A (en) * | 2015-09-15 | 2015-12-09 | 河南省超亚医药器械有限公司 | Medicament for treating hyperostosis and medicament-separated moxibustion of medicament |
| CN105147446A (en) * | 2015-09-30 | 2015-12-16 | 河南省超亚医药器械有限公司 | Intelligent constant-temperature hot-compressing medicine patch |
Non-Patent Citations (3)
| Title |
|---|
| 吕迎春等: "中医辨证治疗慢性溃疡性结肠炎37例", 《现代中西医结合杂志》 * |
| 蔡莉君: "穴位敷贴结合针刺四缝穴治疗小儿疳积30例疗效观察", 《中国中西医结合儿科学》 * |
| 马毅等: "复方丁香开胃贴治疗小儿慢性腹泻疗效观察", 《中国实用医药》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109589203A (en) * | 2018-10-22 | 2019-04-09 | 清华大学 | The heating paste of temperature control film and the spontaneous hotting mask of constant temperature based on organic phase-change |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104287298A (en) | Healthcare shoe and making method thereof | |
| JP2005501851A (en) | Composition for removing toxins | |
| CN106362069A (en) | Medicinal composition for treating gastritis, medicated ironing plaster prepared from medicinal composition, and preparation method of medicated ironing plaster | |
| CN104511090A (en) | Nymphaea tetragona naval warm-compress plaster | |
| CN106729100A (en) | With anti-inflammatory, the external application Chinese medicine health care preparation of beauty and preparation method thereof | |
| CN102861292B (en) | Medicament for treating esophageal cancer and preparation method thereof | |
| CN105616984A (en) | Crinkle-removing beauty cream containing herba leonurus and preparation method thereof | |
| CN105663700A (en) | Wrinkle resistance and beauty treatment cream making method and beauty treatment cream thereof | |
| CN101239128B (en) | Menstruation-regulating face-nourishing Chinese medicinal composition and preparation thereof | |
| CN104815045A (en) | Traditional Chinese medicine prescription for Chinese medicine acupuncture and preparation method | |
| CN103990018A (en) | Antidiabetic traditional Chinese medicine preparation | |
| CN103417836B (en) | Chinese medicine composition for the treatment of tumor and preparation method thereof | |
| CN102475875A (en) | Traditional Chinese medicine preparation for external use and preparation method thereof | |
| CN105902644A (en) | Traditional Chinese medicinal composition for treating cervical spondylopathy, and preparation methods thereof | |
| CN104667002A (en) | Medicine for treating stomach cancer | |
| CN105833099A (en) | Foot bath salt capable of relieving dysmenorrheal and preparation method thereof | |
| CN105641226A (en) | Hot-compress salt for treating dysmenorrhea and preparation method | |
| CN104666998A (en) | Traditional Chinese medicine composition used for treating hypertension | |
| CN104306432A (en) | Natural drug preparation for bath and skin care and preparation method thereof | |
| CN104940864A (en) | External liquid mucilage meridian-warming pellet and production method thereof | |
| CN105056072A (en) | Orally-taken medicine for treating arrhythmia | |
| CN1150887C (en) | Dongxing foot lotion | |
| CN103191349A (en) | Traditional Chinese medicine preparation for treating nephritis | |
| CN103977223A (en) | Traditional Chinese medicinal composition for dispelling cold and dredging orifices and preparation method thereof | |
| CN100490866C (en) | Ready prepared Chinese medicine for treating deep source nasal congestion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170201 |
|
| RJ01 | Rejection of invention patent application after publication |